Fizazi, Karim <br/><br/>
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.  [electronic resource] 

 -  Lancet (London, England)  Mar 2011 
 - 813-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(10)62344-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Bone Density Conservation Agents--adverse effects<br/>Bone Neoplasms--drug therapy<br/>Denosumab<br/>Diphosphonates--adverse effects<br/>Humans<br/>Imidazoles--adverse effects<br/>Male<br/>Middle Aged<br/>Orchiectomy<br/>Prostatic Neoplasms--pathology<br/>RANK Ligand--adverse effects<br/>Zoledronic Acid